Vela Diagnostics Launches HIV Genotyping Assay for Research Use Only

By Vela Diagnostics

2016-09-19

Singapore (September 19, 2016) – Vela Diagnostics announced today that the Next-Generation Sequencing (NGS) based Sentosa® SQ HIV Genotyping Assay is now launched for research use only.

Covering the protease, reverse transcriptase and integrase gene regions, the assay rapidly calls for and detects drug resistant mutations in HIV positive samples.

The Sentosa® SQ HIV Genotyping Assay is designed to run on the Sentosa® SX101 instrument for automated extraction and NGS library prep and the Sentosa® SQ301 sequencer.

The test demonstrated unprecedented sensitivity in 111 blood samples from HIV-1 patients, detecting all 100% of resistance mutations.

Using next-generation sequencing, researchers can now determine the clinical relevancy of these mutations.

Vela Diagnostics is planning for CE-IVD application for this test by 2016.

Go back